{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:21:59Z","timestamp":1791411719714,"version":"4.3.3"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2018,6,13]]},"DOI":"10.3233\/jpd-181329","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T10:57:34Z","timestamp":1526986654000},"page":"247-258","source":"Crossref","is-referenced-by-count":68,"title":["What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson\u2019s Disease: A Post Hoc Analysis"],"prefix":"10.1177","volume":"8","author":[{"given":"Dilan","family":"Athauda","sequence":"first","affiliation":[{"name":"Sobell Department of Motor Neuroscience, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Maclagan","sequence":"additional","affiliation":[{"name":"UCL Comprehensive Clinical Trials Unit (UCL CCTU)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Budnik","sequence":"additional","affiliation":[{"name":"Leonard Wolfson Experimental Neuroscience Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zampedri","sequence":"additional","affiliation":[{"name":"Leonard Wolfson Experimental Neuroscience Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Hibbert","sequence":"additional","affiliation":[{"name":"UCL Comprehensive Clinical Trials Unit (UCL CCTU)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Skene","sequence":"additional","affiliation":[{"name":"UCL Comprehensive Clinical Trials Unit (UCL CCTU)"},{"name":"University of Surrey, Surrey Clinical Trials Unit, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashfia","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"UCL Comprehensive Clinical Trials Unit (UCL CCTU)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iciar","family":"Aviles-Olmos","sequence":"additional","affiliation":[{"name":"Sobell Department of Motor Neuroscience, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Limousin","sequence":"additional","affiliation":[{"name":"Sobell Department of Motor Neuroscience, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[{"name":"Sobell Department of Motor Neuroscience, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-181329_ref1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-181329_ref2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson\u2019s disease: Non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181329_ref3","doi-asserted-by":"crossref","first-page":"e0133002","DOI":"10.1371\/journal.pone.0133002","article-title":"Sex differences in clinical features of early, treated Parkinson\u2019s disease","volume":"10","author":"Augustine","year":"2015","journal-title":"PLoS One"},{"key":"10.3233\/JPD-181329_ref4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1","volume":"8","author":"Parkes","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.3233\/JPD-181329_ref5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.3233\/JPD-181329_ref6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20844","article-title":"International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: The NMSQuest study","volume":"21","author":"Chaudhuri","year":"2006","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181329_ref7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/WCO.0000000000000112","article-title":"Premotor and nonmotor features of Parkinson\u2019s disease","volume":"27,","author":"Goldman","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.3233\/JPD-181329_ref8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: A double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord"},{"key":"10.3233\/JPD-181329_ref9","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0b013e3181c0d416","article-title":"International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease","volume":"73","author":"Martinez-Martin","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JPD-181329_ref10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mds.23939","article-title":"Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson\u2019s disease","volume":"27","author":"Gallagher","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181329_ref11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ene.12165","article-title":"Assessing the non-motor symptoms of Parkinson\u2019s disease: MDS-UPDRS and NMS Scale","volume":"22","author":"Martinez-Martin","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-181329_ref12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0891988715606232","article-title":"Diagnostic validity and factor analysis of Montgomery-Asberg Depression Rating Scale in Parkinson disease population","volume":"29","author":"Ketharanathan","year":"2016","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.3233\/JPD-181329_ref13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.parkreldis.2014.03.010","article-title":"The utility of the Mattis Dementia Rating Scale in Parkinson\u2019s disease mild cognitive impairment","volume":"20","author":"Pirogovsky","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-181329_ref14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ctim.2016.09.008","article-title":"Multi-dimensional analysis on Parkinson\u2019s disease questionnaire-39 in Parkinson\u2019s patients treated with Bushen Huoxue Granule: A multicenter, randomized, double-blinded and placebo controlled trial","volume":"29","author":"Li","year":"2016","journal-title":"Complement Ther Med"},{"key":"10.3233\/JPD-181329_ref15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp.69.1.67","article-title":"The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson\u2019s disease","volume":"69","author":"Schrag","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-181329_ref16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","article-title":"Determining minimally important differences for the PDQ-39 Parkinson\u2019s disease questionnaire","volume":"30","author":"Peto","year":"2001","journal-title":"Age Ageing"},{"key":"10.3233\/JPD-181329_ref17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","article-title":"The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: Results from an international pilot study","volume":"22","author":"Chaudhuri","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181329_ref18","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"10.3233\/JPD-181329_ref19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-181329_ref20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","article-title":"Depression and Parkinson\u2019s disease: current knowledge","volume":"13","author":"Marsh","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.3233\/JPD-181329_ref21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.3233\/JPD-181329_ref22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/JPD-171068","article-title":"Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines","volume":"7","author":"Ventorp","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-181329_ref23","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00702-015-1437-x","article-title":"Quantitative assessment of non-motor fluctuations in Parkinson\u2019s disease using the Non-Motor Symptoms Scale (NMSS)","volume":"122","author":"Storch","year":"2015","journal-title":"J Neural Transm"},{"key":"10.3233\/JPD-181329_ref24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson\u2019s disease: Clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-181329_ref25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: A real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-181329_ref26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov Disord"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-181329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:46:15Z","timestamp":1777610775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-181329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":26,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jpd-181329","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]}}}